• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Reported Saturday, Incyte's Povorcitinib Achieves Up To 57% HiSCR75 And 29% HiSCR100 At Week 54 In Phase 3 STOP-HS Trials, With NDA And MAA Under Regulatory Review

    Benzinga·03/30/2026 06:49:58
    Listen to the news
    • Phase 3 data from the STOP-HS program demonstrate povorcitinib's substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS).
    • Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100.
    • Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54.
    • The overall safety profile of povorcitinib through 54 weeks is con